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Summary. Claudins are the main protein components of
tight junctions (TJs) which function as selective barriers
by controlling paracellular diffusion, maintain cellular
polarity and play a role in signal transduction. The
expression pattern of the 24 known members of the
claudin family proved to be organ and tissue specific.
The up- or downregulation of individual claudins has
been described, especially during carcinogenesis. A
significant increase of claudins-1 and -7 was detected in
premalignant cervical lesions and invasive cancer
compared with normal cervical epithelia. Claudins-3 and
-4 were elevated in endometrial cancer. Claudin-1
overexpression characterized type II (seropapillary)
endometrial carcinoma, while claudin-2 was elevated in
type I (endometrioid) carcinoma. Claudins-3 and -4 were
highly expressed in serous ovarian carcinoma. The
expression data on claudins in different premalignant
and malignant alterations suggest that these proteins
might serve as diagnostic and prognostic markers and
might be targets for future therapy.
Key words: Claudins, Tight junction, Cervical cancer,
Endometrial cancer, Ovarian cancer
Introduction
Cell adhesion is highly important in the organization
of the polarized structure of epithelial tissue and is
critical in cell-cell and cell-extracellular matrix (ECM)
interactions (Balda and Matter, 2008). Intercellular
junctions, of which several types are known, define
epithelial organization and preserve tissue integrity. The
junctional complex is composed of tight junction (TJ)
(zonula occludens), adherens junction, desmosome and
gap junction. The TJ is a continuous circumferential
beltlike structure at the most apical pole of epithelial
cells. TJs function as selective barriers by controlling
paracellular diffusion of water and ions (permselectivity,
gate function), they are responsible for the maintenance
of cell polarity (fence function), and are connected with
actin cytoskeleton (Tsukita et al., 2008). More recently it
has become clear that TJs play role in cell signaling and
are involved in the regulation of cell proliferation (Balda
and Matter, 2008; Paris et al., 2008; Tsukita et al., 2008).
Electron microscopic and freeze fracture studies
suggested the presence of integral membrane proteins in
TJs, however it was only in 1993 that Furuse et al.
discovered the first TJ protein named occludin (Furuse et
al., 1993). It was soon proved that the molecular
backbones, the main constituents of TJ strands are a
large family of transmembrane proteins, the claudins
(20-27 kDa) (Furuse et al., 1998). The claudin protein
family has 24 members (at least in mice and humans)
and homotypic and/or heterotypic intercellular
interactions are formed between the different claudin
types (Tsukita et al., 2001). TJs structurally consist of
transmembrane and membrane-associated proteins and
are linked to components of the cytoskeleton
(Schneeberg and Lynch, 2004). The transmembrane
claudins, together with occludin, junctional adhesion
molecules 1, 2 (JAM 1, 2) and the newly discovered
integral membane protein tricellulin form bi- or
tricellular interactions between neighboring cells
(González-Mariscal et al., 2007). Claudins consist of a
larger and smaller extracellular loop, 4 transmembrane
domains and C- and N-terminal ends, which bind to
other proteins such as ZO-1,-2,-3 and interact with
perijunctional filamentous actin both directly and
indirectly through other proteins such as α-catenin and
cingulin, connected to the cytoskeleton (Shen et al.,
2008). 
The expression profile of individual claudins varies
among tissues, showing a characteristic claudin pattern.
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These data suggest that different claudins play specific
physiological roles in different tissues (Honda et al.,
2007). More recently, a dynamic model of TJ
components demonstrated that the TJ undergoes constant
remodeling, which may contribute to TJ assembly and
regulation. Rapid TJ remodeling occurs in response to
extracellular stimuli (Shen et al., 2008). The presence of
phosphorilation sites and PDZ binding motives in
claudins suggest a role in signal transduction for
proliferation and other cellular functions (Honda et al.,
2007).
Recently, several publications have proved
alterations in the expression of different TJ proteins, first
of all claudins in cancer cells. Up- or downregulation of
different types of claudins has been described (for
reviews see Morin, 2005; Hewitt et al., 2006; Oliveira
and Morgado-Díaz, 2007; Förster, 2008; Tsukita et al.,
2008). Changes of claudin expression at gene and
protein levels during carcinogenesis were detected,
suggesting the role of claudins as progression markers in
several cancers. The expression pattern of claudins in
tumors proved to be organ and tissue dependent
(Kleinberg et al., 2008).
Alterations of claudin expression have been
observed in gynecological cancers as well, including our
studies on cervical and endometrial cancers and
premalignant lesions (Sobel et al., 2005a,b, 2006). The
current review summarizes the most important
alterations observed during the most common
gynecological malignancies such as cervical,
endometrial and ovarian cancers and premalignant
lesions.
Claudin expression in cervical cancer and
premalignant lesions
Cervical cancer is the second most common cancer
among women worldwide after breast cancer. The
progression of early changes from normal cervical
squamous epithelium to premalignant cervical
intraepithelial neoplasia (CIN I, II, III), in situ carcinoma
(CIS) and invasive cancer is well defined (Baak et al.,
2009; Wang and Sherman, 2009). Cell-to-cell contacts
are especially important in the highly resistant cervical
epithelium, whose organization is altered during
carcinogenesis even in early lesions. A large body of
knowledge, based on the discovery of H. Zur Hausen
(1976a,b), supports that the high risk types of human
papilloma virus (HPV) are strongly associated with
cervical cancer.
Several molecular changes have been described
during the progression of cervical cancer, even from the
early stages. Aberrations of p16 INK4A, p27KIP1, cyclin E,
CDK4 are considered early events in HPV 16- and 18-
associated carcinoma, whereas others, like cyclin D1 and
p53 alterations are late events (Bahnassy et al., 2007).
Overexpression of cyclins, especially cylin A, is a poor
prognostic factor in cervical cancer (Shiohara et al.,
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Table 1. Expression, up- or downregulation of claudins in gynecological cancers.
Tissue Expression of claudins References
Cervix Studied: 1, 2, 3, 4, 7,
Normal 1, 2, 4, 7 present Chen et al., 2003; Lee et al., 2005; Sobel et al., 2005a,b
CIN/CIS 1, 2, 4, 7 up Chen et al., 2003; Lee et al., 2005; Sobel et al., 2005a,b
Invasive carcinoma 1, 2, 4, 7 up Chen et al., 2003; Lee et al., 2005; Sobel et al., 2005a; Vázquez-Ortíz et al., 2005
Endometrium Studied: 1, 2, 3, 4, 5, 7
Normal 1, 2, 3, 4, 5, 7 present Soini, 2005; Sobel et al., 2006
Endometriosis 3, 4, 7 down Gaetje et al., 2008; Pan et al., 2008
Hyperplasia 3, 4 up Sobel et al., 2006; Pan et al., 2008
Carcinoma (Not specified) 1, 2, 3, 4, 5, 7 up Soini, 2005
Type1 1 down, 2 up, 7 up (1) 3, 4 up (1, 2) (1) Sobel et al., 2006; (2) Pan et al., 2008
Type2 1 up, 2 down (1) 3, 4 (1, 2) up (1)Sobel et al., 2006; (2)Santin et al., 2007
Ovarium Studied: 1, 2, 3, 4, 5, 7, 10
Adenoma, Cystadenoma 3, 4 down Hough et al., 2000; Rangel et al., 2003; Heinzelmann-Schwarz et al., 2004; Hibbs
et al., 2004; Lu et al., 2004; Santin et al., 2004; Agarwal et al., 2005; Morin, 2005,
Bignotti et al., 2006; Soini, 2005; Zhu et al., 2006; Choi et al., 2007; Honda et al.,
2007; Litkouhi et al., 2007; Kleinberg et al., 2008; Huang et al., 2009
Bignotti et al., 2006; Tassi et al., 2008
Bignotti et al., 2006
Serous carcinoma 3, 4 up7 up
10 up
of invasive cervical cancer cases as compared with
CIN/CIS lesions, although claudin expression in
invasive carcinoma was still higher than in normal
cervical epithelium (Fig. 1c-e). Further, claudin-2
colocalized with another TJ protein, occludin, in normal
cervical squamous epithelium and both were elevated in
CIN/CIS alterations (Sobel et al., 2005b). The HPV
receptor syndecan-1 colocalized with claudins-1, -4 and
-7 in normal cervical epithelium, but increased in
CIN/CIS lesions (Sobel et al., 2005b). Lee et al (2005)
analyzed 89 cervical samples and detected gradually
increased expressions of claudins-1 and -7 in accordance
with progression from low grade squamous
intraepithelial lesion (LSIL) to high grade SIL (HSIL)
and invasive carcinoma. These authors, however, could
not detect claudins-1 and -7 in normal cervical epithelia.
Contrary to their study, our observations and those of
others proved the presence of claudin-1 in normal
squamous epithelia in the cervix and other organs such
1609
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Fig. 1. Claudin-1 by immunohistochemistry in normal cervical epithelium (a), cervical intraepithelial neoplasia III (b), invasive carcinoma (c, d) and
lymphatic invasion (d). Hematoxylin stain. a, c-e, x 250; b, x 100; insert in a, x 400
2005). P16INK4A became a predictive biomarker in
cervical preinvasive and invasive neoplasia (Murphy et
al., 2005). Alterations of different types of keratins have
been observed in cervical cancer (Carrilho et al., 2004;
Regauer and Reich, 2007). Ep-CAM expression in
cervical epithelia correlated with increased proliferation
and disappeared in terminal differentiation (Litvinov et
al., 1996).
In the majority of cancers, claudins are
downregulated and decreased gene and protein
expressions can be detected (Tökés et al., 2005a,b). In
cervical cancer, however, several claudins are
upregulated (Table 1). Our group (Sobel et al., 2005a),
studying 105 cervical samples, detected that claudins-1,
-2, -4, and -7 were significantly increased in CIN I/II and
CIN III/CIS lesions compared with normal epithelium
(Fig. 1a,b). Expression of claudins-1 and -7 was highest
in CIN III/CIS alterations (Fig. 1b). Reduced expression
of claudins-1, -2, -4 and -7 was observed in the majority
as the esophagus (Györffy et al., 2005; Lioni et al.,
2007), tongue (Bello et al., 2008) and oral mucosa (dos
Reis et al., 2008). Other studies (Chen et al., 2003),
corresponding with previous observations, detected
increased claudin-1 expression by cDNA and tissue
microarray in premalignant cervical lesions and in
invasive cancer.
Claudins-1 and -7 are closely related TJ proteins
(Hewitt et al., 2006). It is not surprising that they are
present in the same type of epithelium, as cervical
squamous epithelium and the alterations, up- or
downregulations of the two claudins are parallel in
cervical and other cancers, as in prostatic
adenocarcinomas (Sheehan et al., 2007), tongue cancer
(Bello et al., 2008) and oral squamous carcinoma (dos
Reis et al., 2008). Increased expression of claudin-1 was
detected in melanomas suggesting that it contributes to
melanoma cell motility (Leotlela et al., 2007). Loss of
claudin-1 expression correlated with malignancy of
hepatocellular carcinoma (Higashi et al., 2007) and
decreased with recurrence status in breast cancer
(Morohashi et al., 2007). Claudin-1 has been suggested
as a prognostic marker for patient survival in renal cell
carcinomas (Fritzsche et al., 2008).
Increased expression of claudin-1 was detected in
oral squamous cell carcinomas, especially in those with
perineural and lymph node metastases and it was implied
that this protein is associated with aggressive tumor
behavior (dos Reis et al., 2008). Increased claudin-1
overexpression was observed in colorectal cancer,
hinting at a link between overexpression of claudin-1
and colorectal carcinogenesis (Grone et al., 2007). It has
been suggested that overexpression of claudin-1 may
contribute to invasion through destabilization of TJs,
resulting in loss of adhesion (dos Reis et al., 2008). In
another study, however, claudin-1 acted as a metastasis
suppressor and correlated with clinical outcome in lung
adenocarcinoma. Patients with low claudin-1 expression
had shorter overall survival (Chao et al., 2009).
Claudin expression in endometrium, endometriosis
and endometrial carcinoma
Endometrial carcinoma (EC) is the most prevalent
gynecological cancer in the developed countries
(Silverberg et al., 2003; Doll et al., 2008) and is
increasing in frequency compared with cervical cancer
(Mutter et al., 2009). Two biologically and
histopathologically classified distinct types, referred to
as types I and II, correspond to the endometrioid and
non-endometrioid types (Silverberg et al., 2003; Doll et
al., 2008; Mutter et al., 2009). Type I is the more
common form which accounts for >80% of ECs, is low
grade, estrogen-dependent, associated with endometrial
hyperplasia and has better prognosis. Type II is more
aggressive, nonestrogen-related, high grade and lacks
association with endometrial hyperplasia (Goff, 2005;
Sobel et al., 2006). Several genetic abnormalities have
been detected and differently expressed in the two types
of ECs (Hough et al., 2000; Matias-Guiu et al., 2001;
Wu et al., 2003; Hecht and Mutter, 2006; Sobel et al.,
2006; Stewart et al., 2006; Doll et al., 2008; Jia et al.,
2008; Fadare and Zheng, 2009; Mutter et al., 2009) and
a dualistic model of endometrial carcinogenesis was
proposed (Sherman et al., 1995; Lax and Kurman, 1997).
Based on molecular genetic data, ECs likely develop as
the result of stepwise accumulation of genetic
alterations, oncogene activation and tumor suppressor
gene inactivation (Doll et al., 2008). The molecular
pathogenesis, however, is not exactly clear. In this
respect, alterations of TJ proteins, which might play role
in carcinogenesis, are interesting.
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Fig. 2. Positive reaction of claudin-1 by immunohistochemistry in type II (seropapillary, a) and negative reaction in type I (endometrioid, b) endometrial
cancer. Hematoxylin. x 250
Studies have shown increased protein expression of
CLDNs-1, -2, -3, -4, -5 and -7, although type I and II
ECs have not been separated (Soini, 2005). Sobel et al.
(2006) differentiated EC on the basis of claudin
expression. Type I (endometrioid) EC and endometrial
glandular hyperplasia expressed low CLDN-1 and high
CLDN-2 proteins and mRNA. Type 2 (seropapillary,
non-endometrioid) EC showed high CLDN-1 and low
CLDN-2 expression (Fig. 2). CLDN-3 was significantly
higher in both types of EC, compared with normal
proliferative phase endometrium. Claudin-4 was higher
in type I carcinoma compared with the proliferative
phase. More recently Santin et al. (2007), using gene
expression profiling, identified high expression of
CLDNs-3 and -4 in a limited set of uterine serous
papillary carcinoma (type II). This finding is important
because CLDNs-3 and -4 serve as low- and high-affinity
receptors for the cytotoxic Clostridium perfringens
enterotoxin (CPE), so it might have therapeutic
significance. 
Altered expression of claudins-3 and -4 was detected
in ectopic endometrium of 35 women with
endometriosis (Pan et al., 2008). Expression of claudins-
3 and -4 was significantly lower in ectopic endometrium
than in healthy controls both at mRNA and protein
levels. Authors suggest that down-regulation of claudins
in ectopic endometrium might play a pathogenetic role
in endometriosis (Pan et al., 2008). Expression of
claudins-3 and -4 was found to be upregulated in
endometrial atypical hyperplasia and endometrioid
adenocarcinoma, compared with normal endometrium
(Pan et al., 2007). Thirteen members of the claudin
family were analysed by microarray analysis in
endometrium and peritoneal endometriosis (Gaetje et al.,
2008). Diminished expression of claudins-3, -4 and -7
was detected in ectopic endometrium.
Claudin expression in ovarian cancer
Ovarian cancer (OC) is the sixth most common
malignancy in women and the leading cause of mortality
from gynecological cancer, at least in the USA (Greenlee
et al., 2000). Difficulties in diagnosis and treatment of
OC is partly responsible for the low survival rate
(Stewart et al., 2006). Large-scale serial analysis of gene
expression has shown genes differently expressed in OC
(Hough et al., 2000; Stewart et al., 2006). Some of the
genes overexpressed in OC are claudins-3, -4, HE4,
mucin-1, epithelial cell adhesion molecule, etc (Hough
et al., 2000; Hibbs et al., 2004; Gilks et al., 2005;
Stewart et al., 2006). Serous carcinoma is the most
common type of OC, and has been graded as a
moderately and poorly differentiated carcinoma (Hsu et
al., 2005). A dualistic model divides OC into low and
high grade, associated with distinct molecular alterations
(Shih and Kurman, 2004). Serum markers, such as CA
125, have been widely used in the detection of OC,
although with varying specificity (Rosen et al., 2005;
Choi et al., 2007). 
Claudin-3 and -4 are receptors for CPE and are
overexpressed in epithelial OC (Rangel et al., 2003; Lu
et al., 2004; Santin et al., 2004; Agarwal et al., 2005;
Morin, 2005; Zhu et al., 2006; Litkouhi et al., 2007;
Kleinberg et al., 2008). The second extracellular loop of
claudins-3 and -4 interacts with CPE and causes lysis of
the cells expressing these two proteins (Katahira et al.,
1997). It was shown that intraperitoneal administration
of CPE caused inhibition of chemotherapy-resistant
human OC xenografts (Santin et al., 2005).
Gene expression studies documented high
expression of claudins-3 and -4 (Hough et al., 2000;
Rangel et al., 2003; Heinzelmann-Schwarz et al., 2004;
Hibbs et al., 2004; Lu et al., 2004; Santin et al., 2004;
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Fig. 3. Strong positive reaction of claudin-4 in serous epithelial ovarian carcinoma. Hematoxylin. a, x 100; b, x 250
Zhu et al., 2004; Bignotti et al., 2006; D’Souza et al.,
2007; Honda et al., 2007; Litkouhi et al., 2007; Zhu and
Sundfeldt, 2007), claudin-7 (Bignotti et al., 2006; Tassi
et al., 2008) and claudin-10 (Bignotti et al., 2006) in OC.
Studies, however, comparing benign ovarian tumors
with OC were less conclusive (Rangel et al., 2003; Zhu
et al., 2006). Both claudins-3 and -4 were, however,
expressed at higher levels in ovarian serous cancers (Fig.
3) than in adenomas and borderline tumors (Choi et al.,
2007). 
Claudin-7 was found to be significantly
overexpressed in all main histological types of ovarian
epithelial carcinomas and in single disseminated cells in
the peritoneal cavity (Tassi et al., 2008). Based on the
above mentioned data, overexpressed claudins might
have a potential role as a novel diagnostic marker. 
Studies suggested that DNA methylation is a
mechanism for claudin-4 in OC and CPE is an agent
binding to it. Litkouhi et al. (2007) treated epithelial
ovarian cells with CPE and detected TJ alterations.
However, claudin-4 overexpression in epithelial OC did
not correlate with survival or other clinical endpoints
and was associated with hypomethylation according to
these authors. Honda et al. (2007) determined that the
loss of claudin-3 expression was not caused by the
absence of Sp1 and Sp3 transcription factors, but rather
by epigenetic factors such as DNA methylation, which
was found to be inversely correlated with expression.
According to these authors, during progression, OC
activates regulatory elements such as enhancers, in order
to express claudins-3 and -4 at high levels detected in the
tumor. D’Souza et al. (2007) showed that claudin-4 may
be phosphorilated by protein kinase C (PKC) in OC cells
and overexpression of a mutated protein mimicking the
phosphorilated state resulted in disruption of barrier
function. Phorbol ester-mediated PKC activation of OC
cells showed that TJ strength decreased and claudin-4
localization altered. 
In a survival analysis of serous ovarian
adenocarcinoma cases, high claudin-3 expression
associated with shorter survival was found to be an
independent negative prognostic factor (Choi et al.,
2007). Claudin-3 and -7 expression in effusions
independently predicted poor survival in OCs (Kleinberg
et al., 2008).
More recently claudin-3 gene silencing with siRNA
was found to suppress ovarian tumor growth and
metastasis in mouse tumor models (Huang et al., 2009).
Intratumoral injection of lipidoid/claudin-3 siRNA into
human OVCAR-3 xenografts resulted in the silencing of
claudin-3 with reduction of cell proliferation, tumor
growth and increase of apoptotic cells (Huang et al.,
2009). These data suggest that a lipid-like delivery
system for claudin-3 siRNA might be a potential
therapeutic option for OC (Huang et al., 2009).
Claudins-3 and -4 are among the most highly and
consistently upregulated genes in OC (Honda et al.,
2007; Huang et al., 2009), suggesting that these TJ
proteins play role in ovarian carcinogenesis and
metastasis formation (Agarwal et al., 2003; Huang et al.,
2009). Claudin-4 was found to be upregulated in other
tumors, as in pancreatic cancer (Michl et al., 2001;
Nichols et al., 2004; Borka et al., 2007), however, it was
associated with decreased invasiveness (Michl et al.,
2003). This suggests that claudins play different roles in
different organs and their cancers.
Concluding remarks
Claudins show similar pattern in the normal
squamous epithelia of several organs such as cervix, oral
mucosa, tongue, esophagus. Claudins-1 and -7 seem to
be the most characteristic, claudin-3 is lacking and
claudin-4 is lowly expressed in normal cervical
squamous epithelia. Individual claudins, especially
claudins-1 and -7, show increased expression during the
early stages of carcinogenesis and in premalignant
lesions and are higher in invasive carcinoma than in
normal epithelia. The increased expression of claudins-1
and -7 might be useful as a marker in the detection of
cervical premalignant and malignant cancers. 
Endometrial cancer has shown increased protein
expression of several claudins, such as CLDNs-1, -2, -3,
-4, -5 and -7. Claudin-1 might serve as a marker to
differentiate type I and type II endometrial cancer, so it
might have prognostic significance. 
Epithelial ovarian cancer is highly characterized by
consistently upregulated CLDNs-3 and -4. It has recently
been suggested that the highly restricted expression
pattern of claudins in normal tissues, their frequent
upregulation or ectopic activation in a diversity of
cancers and their cell membrane-associated localization
make claudins a good target for future therapy (Sahin et
al., 2008).
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